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ABSTRACT

Kho, Soon Jye. PhD. Department of Computer Science and Engineering, Wright State
University, 2021. Sample Mislabeling Detection and Correction in Bioinformatics
Experimental Data.

Sample mislabeling or incorrect annotation has been a long-standing problem in
biomedical research and contributes to irreproducible results and invalid conclusions.
These problems are especially prevalent in multi-omics studies in which a large set of
biological samples are characterized by multiple types of omics platforms at different times
or different labs. While multi-omics studies have demonstrated tremendous value in
understanding disease biology and improving patient outcomes, the complexity of these
studies may increase opportunities for human error. Fortunately, the interrelated nature of
the data collected in multi-omics studies can be exploited to facilitate the identification
and, in some cases, correction of mislabeling errors. The dissertation proposed a pipeline
comprising statistical and machine learning techniques to identify mislabeled samples and
correct the sample labels. Expected correlations between copy number variation, gene
transcript abundance, protein abundance and microRNA expression were used to identify
mislabeled samples. In datasets with only two omics data, the label corrections were
performed by exploiting gender-specific indicators of the mislabeled samples; whereas in
datasets with more than two omics data, a network topology realignment method was
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proposed to perform label correction. We demonstrated the effectiveness of the pipeline in
several cancer datasets by simulation experiments. The pipeline was then performed on
several public multi-omics datasets and in overall, 2.71% of the samples are found to be
mislabeled.
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1.

INTRODUCTION

Omics refers to the global and comprehensive assessment of a set of biological molecules.
The advances in omics technologies in the past two decades have had a profound impact
on the biomedical sciences. Diverse types of omics data have been generated and studied
extensively to understand complex biological processes. Transcriptomics data has been
well explored in the literature for associations with specific diseases with the intent of
understanding and/or predicting susceptibility to disease, morbidity, and disease
progression. Ma et al. (2003) generated gene expression data of breast cancer tissues of
distinct stages (premalignant, preinvasive and invasive) and distinct grades (grade I, II, and
III). They found that the gene expression exhibits a similar pattern among different stages,
suggesting the alteration of gene expression is already present in the preinvasive stage. In
contrast with stages, a distinct gene expression pattern was observed in different grades
and several genes were identified to be differentially expressed in Tumor grade III. Tonon
et al. (2005) characterized the genomic profile of non-small cell lung cancer (NSCLC) and
identified 319 copy number alterations (CNA). Recurrent CNAs in different samples allow
the grouping into minimal common regions (MCR). The authors found 93 MCRs in total
which covers a number of tumor suppressor genes and oncogenes found to be implicated
in NSCLC. Rai et al. (2002) profiled peptide abundance of plasma of patients diagnosed
with ovarian cancer. Four biomarkers were identified to have high discriminatory power
for cancer detection.
1

1.1

Multi Omics Studies
Omics technology provides a high throughput approach to identify a list of

differences associated with the diseases, providing insights on the different biological
processes occurring in patients and normal individuals. However, the insights from single
omics studies may be limited as the data only reveals the difference of one set of biological
molecules and does not uncover the flow of such information to other molecules. As such,
researchers may adopt a system biology approach and integrate multiple omics in studies
of a variety of diseases. Over the past two decades, rapid development of omics
technologies has facilitated the measurement of variations in form, abundance, and state of
a wide range of biological macromolecules.

Some of the more common omics

technologies include:
-

Genomics - assessment of DNA sequence variations among and within individuals,
tissues, and cells.

-

Transcriptomics - assessment of RNA transcript abundance or state. Variations
exist to allow specific observation of messenger RNA (mRNA) transcripts,
microRNA (miRNA) transcripts, alternative splicing of mRNA transcripts,
ribosome translation of mRNA transcripts.

-

Metagenomics - exploration of the collective genome of a population of organisms.

-

Epigenetics - exploration of changes in genomic state that do not involve sequence
variation, including chromatin structure and DNA methylation state.

-

Proteomics - assessment of the relative abundance of expressed proteins.
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-

Phosphoproteomics - assessment of the relative abundance of proteins containing a
phosphate group as a result of posttranscriptional modifications.

-

Metabolomics - assessment of the presence and relative abundance of metabolites,
often assayed using liquid chromatography-mass spectrometry (LC-MS) or nuclear
magnetic resonance (NMR) spectroscopy.

Mertins et al. (2016) characterized genomic, transcriptomic, proteomic and
phosphoproteomic profiles of 105 breast cancer samples. The authors performed
integrative analysis on these omics landscapes and revealed several genomic alterations
that affect the proteomic abnormality. Notably, the loss of chromosome 5q exhibits the
most trans-association where loss of CETN3 and SKP1 is associated to elevated expression
of epidermal growth factor receptor (EGFR), and SKP1 loss to increased SRC tyrosine
kinase. On the other hand, Ding et al. (2018) conducted an ambitious study in which they
inspected 11,000 tumor samples across 33 different human cancer types. The study aims
to elucidate the molecular processes governing oncogenesis by uncovering the influence
of somatic mutation to the carcinogenesis process. The study uncovers the association of
somatic mutations with other omics (epigenome, transcriptome, and proteome) which helps
in identifying the driver genes and therapeutic targets.
Multi omics studies are becoming more common in recent years. The search term
“multi omics” retrieved over 1121 publications in Pubmed in 2020, compared to 17
publications in 2010 (Figure 1.1). The increasing popularity of multi omics studies has
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called for a repository suited for handling and disseminating this sort of system biology
data. The Cancer Genome Atlas (TCGA) is a pan-cancer analysis project that has profiled
and analyzed a large number of human tumors to discover molecular aberrations at the
DNA, RNA, protein, and epigenetic levels (Weinstein et al., 2013). It is by far the largest
such repository that has been made available for study by the scientific community.

Figure 1.1: Number of “multi omics” related publications in PubMed.

1.2

Sample Mislabeling

Multi omics studies allows researchers to dissect a biological process from different aspects
and understand it via a holistic approach. Consequently, a multi omics study is inevitably
a large scale study that involves collaboration among researchers of different specialties.
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The large scale of such study does not come without consequences. Human errors can occur
at multiple steps in the experimental process including sample collection, transportation,
sample analysis and data generation, and data analysis and interpretation. Sample
mislabeling is particularly concerning as it might go unnoticed and can introduce
significant noise into the data.
While the majority of experiments and results reported in the scientific literature
are undoubtedly accurate and reproducible, there nevertheless remain numerous instances
of identified experimental and procedural errors. Toker et al. (2016) looked for
discrepancies between gene expression-inferred and investigator-annotated sex in 70
human microarray datasets. The authors found that among 4160 samples, 83 (2%) of them
are mislabeled. These mislabeled samples are scattered across 32 datasets, showing an
alarmingly high prevalence of mislabeling in datasets where 46% (32 / 70) of datasets
contain mislabeled samples.
Other than biomedical research settings, sample mislabeling and data mishandling
have been long-standing problems in medical settings. The U.S. Institute of Medicine
(Kohn et. al, 2007) published a report entitled To Err is Human which estimates as many
as 98,000 die in any given year from medical errors. The report increased the awareness of
medical errors which in turn pushed the initiative for prevention and mitigation. With the
intention of improving patient safety, Astion et al. (2003) investigated reported incidents
in the laboratory which could potentially cause adverse events to patients. In their study,
129 incidents were reported in a 16 months period which have the potential to cause
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adverse events, though the errors may have been intercepted before causing harm to the
patient. The authors then examined the factors for these incidents. Some factors, such as
incorrect requisition, missing collection of specimens, lost or delayed specimen,
suboptimal or ruined specimens, led to the failure or delay of data generation. Though
unfortunate, these factors are easily recognized and corrected. In contrast, other factors
such as specimen mislabeling and data entry errors are harder to detect and could cause
serious harm as these factors can result in incorrect interpretation of the patient’s condition.
Moreover, specimen mislabeling and data entry errors are not uncommon and constitute
26% of all the incidents examined.

1.3

Consequences of Sample Mislabeling

In the medical settings, sample mislabeling may incur unnecessary patient discomfort,
additional facilities and labor cost, increase morbidity and medical cost. Astion et al. (2003)
reported that 5% of laboratory incidents caused actual adverse events. Valenstein et al.
(2006) estimated that the rate of adverse events out of mislabeling events is ~5.29% (324
out of 6123).
In biomedical research settings, sample mislabeling may cause statistical power
loss, irreproducible results, invalid conclusions and increased research cost. Statistical
power loss has been a concern in the genetics research community. Simulation showed that
sample mislabeling has disproportionate effects on the power to detect genetic associations
in genome-wide studies, especially when the sample size is small (Buyske et al., 2009;
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Edwards et al., 2005). Another study reported that sample mislabeling presents a problem
in detecting genetic variants associated with diseases, specifically those variants with small
genetic effect and low frequency (Samuels et al., 2009).
Correctness and reproducibility of experiments are cornerstones of the scientific
method. However, these are significantly impacted by sample mislabeling. In the year
2007, Rae et al. (2007) found that the cell line MDA-MB-435, famously known as the
“triple-negative breast cancer” cell line, is actually derived from a melanoma cell line. Yet,
despite the identification of the error, researchers still published studies using the cell line
in international peer reviewed journals over the following years. Prasad & Gopalan (2015)
reported that a total of 890 published studies have used the cell line as a model for human
breast cancer and 219 among them are published after the year 2007. The conclusions of
notable studies that investigate the effect of drugs using this cell line may thus be
questionable.
While mislabeling of one sample does not always falsify the claims of a study
(depending on the total number of samples in the study), mislabeling of a significant
portion of samples may invalidate the conclusion. Moloney et al. (2016) published a study
which investigated the genetic underpinnings of amyotrophic lateral sclerosis (ALS) but
the study was retracted later as it was discovered that the mouse line was mislabeled. Mice
mislabeled as expressing wild-type MATR3 were actually expressing the mutant variant
of the MATR3 gene with a mutation of F115C. While the retraction of published studies

7

may incur unnecessary research and labor costs, this is nevertheless a preferable outcome
compared to undiscovered errors resulting in false study conclusions.
Many experimental assays and protocols include quality control checks that can
help to verify the correctness of the experimental conditions and instruments used.
However, gross human error such as sample mislabeling or incorrect analysis assumptions
remain difficult to detect and correct, especially in high-throughput multi-omics studies.
Given the high prevalence and severe consequences of sample mislabeling, it is desirable
to have a quality check system to ensure the correctness of data. This not only safeguards
the patient safety in medical settings, but also improves reproducibility of a study and
prevents any invalid claim in biomedical research settings.
Detecting individual mislabeling is a nontrivial task. However, unlike many other
multi-omics problems which suffer from the well-known curse of dimensionality (Sen &
Others, 2005) - decrease in classification performance as the number of independent
variables increases - it may be possible to harness the plentitude of observed features
typical to these studies to increase confidence for mislabeling identification and even
correction. As multi-omics studies are becoming more commonplace, it is both desirable
and feasible to develop a scalable automated approach.
We hypothesized that if more dimensions of data are generated, it could provide
more information to determine the source of error and help in relabeling the data
automatically to the individual level. Specifically, we address two research questions here:
1) Can correlation signals across different omics data accurately identify individual
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mislabeling errors? and 2) Is the information in typical multi-omics systems biology studies
sufficient to afford automated correction of mislabeling errors?

9

2.

LITERATURE REVIEW

Machine Learning is a method of data analysis that automates analytical model building.
Machine learning approaches, as applied to data analytics, attempt to identify patterns in
observations (generally referred to as instances). Each observation may comprise multiple
variables (or features) collected from a single sample or individual. In cancer
transcriptomics for example, a sample may consist of tens of thousands of gene expression
values from a single tumor tissue sample. In supervised machine learning the learned
patterns are applied to classify the observations into two or more classes (e.g. cancer tissue
versus healthy tissue). Unsupervised machine learning, in contrast, does not associate a
class with each sample. Rather, models are constructed to identify non-uniform distribution
(groupings) of samples (i.e. cluster analysis) or to explain the variance in the samples in
terms of the observed features (e.g. principal component analysis and factor analysis).
More recently, semi-supervised approaches have been developed to perform classification
where only some of the samples have known class labels.
Supervised machine learning is generally carried out in two stages: training and
testing. In the training stage, a model is constructed based on distinct patterns in training
data associated with different classes. In the testing stage, the identified patterns are
exploited to make predictions about future data.
The past several decades have seen significant advances in data availability,
computing power, affordability of storage, and ease of data sharing. These changes, along
10

with improvements in machine learning algorithms, have led to successful application of
supervised machine learning across a wide variety of domains. In many cases, machine
learning methods have performed tasks previously thought to be exceedingly difficult or
impossible to automate (González-Reymúndez et al., 2017; Jagga & Gupta, 2014; Sun et
al., 2008). Successful construction of machine learning-based models, however, generally
requires an abundance of high-quality data. As the use of supervised machine learning
becomes increasingly common, researchers have tried to identify mislabeled instances and
correct their labels before building the model. It is important to note that these studies focus
on detecting class mislabeling instead of individual mislabeling. Class mislabeling refers
to the instance in which a sample's class (e.g. tumor vs healthy tissue) is labeled incorrectly,
while individual mislabeling refers to a sample that is labeled as belonging to the wrong
individual or source. Section 2.1 describes current work in identifying class mislabeling
and Section 2.2 discusses research into identifying individual mislabeling.

2.1

Detecting Class Mislabeling

The problem of mislabeling is particularly concerning in supervised machine learning
applications as labeled samples - which often come from human tissue - are sparse, and
mislabeled instances constitute noise in model building. This would decrease the accuracy
and reliability of the model. Several approaches have been explored for detecting class
mislabeling with the aim of increasing data quality. The methods used in these studies can
be categorized into two different types: classification and statistical approaches.

11

2.1.1 Classification Approaches
As mislabeled instances constitute noise in model building, their presence is reflected in
the decrease of a model’s classification performance. Different studies have utilized
different metrics that define the classification performance of a model. Muhlenbach et al.
(2004) proposed an algorithm to identify training noise that influences class separation with
the aim of minimizing error rate of the classifier model. The authors projected each sample
into a graph and determined edges that connect samples: two samples are connected if there
are no other samples between them. The connections helped to determine if a dataset has
good class separability, having a lower number of edges than a random graph that needed
to be cut in order to obtain well-defined clusters (sub-graphs connected only by samples of
the same class). Then, the sample’s neighbors are examined. An instance is considered
mislabeled if the majority of its neighbors are of different classes. The experiments were
performed on a collection of ten domains from the UCI Repository of Machine Learning
Databases1. The authors also investigated the optimum handling method for the identified
suspected samples. They found that handling suspected samples via the schema of
“relabelling or else removal” (relabel if a suspected sample’s neighbors are of the same
class, otherwise remove) yields a lower error rate in all datasets except Breast Cancer
Dataset, where removing all suspected samples consistently yields the lowest error rate.

1

https://archive.ics.uci.edu/ml/index.php
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Sánchez et al. (2003) inspected different approaches that enhance the classification
accuracy of Nearest Neighbor (NN) classifiers. The experiment was applied on five
datasets from the UCI Repository of Machine Learning Databases1. Different approaches
were performed on the dataset to filter out bad samples, samples that are mislabeled or
outlier. The authors found that the depuration method (use leave-one-out method to predict
a sample’s class using k-NN classifier. The sample is relabeled if it has k’ representatives
among k neighbours, or removed otherwise) yields the best accuracy in 4 datasets: Liver,
Pima, Cancer and Heart Datasets. This study is similar to the previous study (Muhlenbach
et al., 2004), as both studies aim to reduce the noise of training data and improve model
classification.
Venkataraman et al. (2004) developed a method for distinguishing between
correctly labeled and mislabeled data sampled from video sequences. Instead of training
several classifiers as in an ensemble-based method, one single classifier (SVM with a linear
kernel) is trained on multiple representations of the data where each representation is built
by different “discriminating” subspaces that are significant in class separation. Then leaveone-out (LOO) cross-validation is used to identify mislabeled data. Mislabeled data are
those data which the annotated label is inconsistent with the predicted label. The mislabeled
data were removed and the authors showed that removing the mislabeled data increased
the LOO cross-validation accuracy overall.
The above studies focus on filtering noisy and atypical training samples to improve
the quality of training data. The accuracy of relabeling is not evaluated independently.
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Rather, overall classifier performance is the optimization objective. Furthermore, all these
studies use datasets where the number of samples (n) is greater than the number of variables
or features (d), a case that is not commonly seen in omics datasets (d is typically much
greater than n). There are a few studies in detecting class mislabeling in bioinformatics
data.
Malossini et al. (2006) proposed an algorithm that identified mislabeled samples by
label perturbation and data misclassification. The algorithm iteratively perturbed the label
of one instance within cancer microarray datasets and performed n iterations of LOO
classification using an SVM with a linear kernel. An instance was identified to be
mislabeled under two conditions, either: 1) the instance was consistently misclassified after
the perturbation of other instances or, 2) perturbation of that instance resulting in improved
prediction power of the resulting classifier. The first condition is reported to be a better
strategy in identifying mislabeled samples and achieved an average precision of 0.67 and
average recall of 0.92 on three real microarray datasets. One major drawback of this method
is the long execution time as the method requires training of n2 classifiers: n iterations of
LOO classification for n iterations of perturbing the label of instances.
Knights et al. (2011) explored the identification of mislabeled samples solely based
on classifier error rate. They trained prediction models (random forest and nearest
shrunken centroid) and performed prediction on 16S rRNA microbiota data in two
classification tasks (classifying general body habitats like skin vs gut, and classifying
hand/keyboard samples by individual). False positives and false negatives were treated as
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mislabeled instances. They demonstrated that their algorithm was robust to noise and still
able to predict correct labels, but only when the noise level is < 40% and the data exhibited
clear separation between classes. The authors recognized that this approach will not be
useful in a harder classification task where the data separation between classes is very
subtle.
Martín-Merino (2013) proposed a similar algorithm to that of the previous study
with two differences: the classifier model is built using SVM with a dissimilarity kernel
and the datasets used are cancer microarray datasets. The sample and labels were mapped
into feature spaces using the dissimilarity kernel and outliers were detected using one-class
classification. The authors performed the algorithm on cancer microarray datasets and
reported that the algorithm is more effective than a traditional SVM with a linear kernel.
All of these studies can be characterized as outlier detection methods, in that they aim at
removing noise to have a better separability between classes and achieve a better
classification performance of models.

2.1.2 Statistical Approaches
In contrast with the studies in the previous subsection, some studies identify mislabeled
instances by observing the statistical distribution of data. Westra et al. (2011) identified
sample mislabeling by observing the deviation of gene expression z-scores in gene
expression Quantitative Trait Loci (eQTL) datasets. The mean gene expression z-scores of
different genotypes were computed. Significant cis-eQTLs, i.e., trait loci that have
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significant influence on expression of some specific genes, were first identified. Loci
whose expression z-scores of those genes were highly distant from their genotype group
mean were identified as mislabeled. The authors performed sample mislabeling checks on
published datasets and found that four out of five datasets contain sample mislabeling.
Overall, 3% of all samples were mislabeled and 15% more significant cis-eQTLs were
identified after correction.
Lynch et al. (2012) took a similar approach, but they observed the misclassification
of genotypes instead of the deviation of gene expression z-score. Similar to the previous
study, significant cis-eQTLs were first identified. Then, the expression values of those
significant genes were used to predict the genotype of samples. Any instances with
inconsistent genotypes (predicted versus annotated) were identified as mislabeled.
Zych et al. (2017) utilized genotype perturbation and identified mislabeled samples
by observing changes in the t-statistic value. The rationale behind this approach is that if a
mislabeled genotype is perturbed to its true label, the overall t-statistic value between
different genotypes would increase and vice-versa. The algorithm achieved an area under
the curve (AUC) of 0.8 to 1.0, depending on genetic similarity of datasets (the more
dissimilar the dataset, the higher the AUC achieved). The authors performed the algorithm
on public worm gene expression datasets (Snoek et al., 2012; van der Velde et al., 2013)
and 1.9% (4 / 208) of C. elegans recombinant cell lines are found to be mislabeled. One
drawback of the algorithm is a high execution time exacerbated by the perturbation of
genotype. Each perturbation requires a new calculation of t-statistics for every genotypes-
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gene pair. The method requires high performance computing when a dataset has a fairly
large set of samples. The worm datasets used in the studies have ~120 single nucleotide
polymorphisms (SNP) but humans have ten of millions. This limits the scalability of the
algorithm.
As with the previously-described classification-based approaches, all of the
statistical approaches mentioned above identified mislabeled samples with the aim of
assuring the correctness of class labels. Further investigation into the source of error is
usually not performed. However, detecting class mislabeling is not sufficient in the field
of precision medicine, where a data instance should not only be correctly assigned to its
class but also attributed to the correct patient.

2.2

Detecting Individual Mislabeling

Very few studies focus on detecting individual mislabeling. Broman et al. (2015) identified
mislabeled samples by inspecting the concordance of gene expression data across different
tissue types. The datasets are generated from six tissue types from the same population of
mice. Every mouse subject had six tissues (adipose, gastrocnemius muscle, hypothalamus,
pancreatic islets, kidney, and liver) extracted and sequenced using an Affymetrix
microarray platform. The rationale of the approach is that the concordance of gene
expression between two tissues from the same mouse should be high. While the authors
were able to identify and correct mislabeled samples to the individual level, the study
focuses on transcriptomics data from several tissues. The method is not directly applicable
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to study designs where only one type of tissue is sampled for different omics. In addition,
the approach does not provide a mechanism for automated correction. Rather, it relies upon
manual intervention to identify mislabeled samples.
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3.

3.1

MATERIALS AND METHODS

Data Collection

Three multi omics datasets were collected from National Institute of Health’s Clinical
Proteomic Tumor Analysis Consortium (CPTAC) 2. These datasets were generated for three
different cancers: colorectal, kidney and lung. Intensive manual inspection has been
performed and there was no observed data mislabeling upon publication.

3.1.1 Colorectal Cancer Dataset (COAD)
The colorectal cancer dataset was merged from two colon rectal cancer cohorts, 85 from
Zhang et al. (2014) and 96 from Vasaikar et al. (2019). Two types of omics data were
collected: transcriptomics and proteomics. Expression level of mRNA was quantified
based on Fragments Per Kilobase of transcript per Million mapped reads (FPKM). Protein
fragmentation and sequencing were performed through Liquid Chromatography with Mass
Spectrometry (LC-MS/MS) and protein abundance was measured based on spectral
counting (the total number of MS/MS spectra acquired for peptides from a given protein).
For both proteomics and RNA-seq data, genes with more than 50% missing values were
removed, except for genes located in X or Y chromosomes. The missing values were
imputed using Random-Forest based imputation (Stekhoven & Bühlmann, 2011) except

2

https://proteomics.cancer.gov/programs/cptac

19

for sex chromosome genes where the missing values were replaced by zero. This resulted
in a total of 17220 gene and 4105 protein features. The proteomics data were then
normalized using quantile normalization whereas the RNA-seq data was normalized using
the trimmed mean of M-values normalization method (TMM) (Robinson & Oshlack,
2010). Since the dataset was integrated from two cohorts, batch correction was performed
on both proteomics and RNA-seq data using Combat (Johnson et al., 2007) after data
normalization. Quality control analysis was performed using metaX (Wen et al., 2017)
before and after batch correction.

3.1.2 Kidney Cancer Dataset (CCRCC)
The kidney cancer dataset (Clear Cell Renal Cell Carcinoma) was collected from Clark et
al. (2019). Two types of omics data were collected: transcriptomics and proteomics. The
expression level of mRNA was quantified based on FPKM while the expression level of
protein was measured based on spectral counting after performing the MS/MS pipeline.
The samples were manually inspected for any sampling error and one sample was removed
due to low self correlation between RNA and Protein profiles (Clark et al., 2019). The
features with missing rate > 50% were filtered and proteomic missing values were imputed
using DreamAI 3, an ensemble algorithm developed during the National Cancer InstituteClinical Proteomic Tumor Analysis Consortium (NCI-CPTAC) Dream Proteomics

3

https://github.com/WangLab-MSSM/DreamAI
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Imputation Challenge4. There were a total of 19275 RNA features and 10127 protein
features. Lastly, the mRNA expression levels and global protein abundances were
normalized to a standard normal distribution.

3.1.3 Lung Cancer Dataset (LUAD)
The lung adenocarcinoma dataset was collected from Gillette et al. (2020). Four types of
omics data were collected: transcriptomics, proteomics, copy number variation (CNV) and
microRNA (miRNA). The RNA transcript read counts were upper-quartile normalized and
transformed into Reads Per Kilobase of transcript, per Million mapped reads (RPKMs).
Protein abundance was quantified based on spectral counting and normalized TMT ratios.
The features with missing rate > 50% were filtered and proteomic missing values were
imputed using the DreamAI tool5. CNV analysis was performed using CNVEX 6, an
algorithm which uses several probabilistic and optimization algorithms to estimate the copy
number from whole genome sequencing (WGS) and whole exome sequencing (WES) data.
Expression of miRNA was quantified using a variant of the small RNA quantification
pipeline developed for TCGA (Chu et al., 2016). The number of features in each omics
dataset are: 19275 (RNAseq), 7556 (proteomics), 19817 (CNV), and 1881 (miRNA).

4

https://www.synapse.org/#!Synapse:syn8228304/wiki/413428
https://github.com/WangLab-MSSM/DreamAI
6
https://github.com/mctp/cnvex
5
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3.2

Mislabeling Simulation

Three mislabeling error patterns were observed in various TCGA or CPTAC datasets:
swapping, duplication and shifting (Clark et al., 2019). These similar error patterns were
introduced into the datasets during simulation and the simulation mechanisms were
described as below.

3.2.1 Swapping
Swapping errors occur when the patient labels of two samples from different subjects are
swapped. Swapping errors can occur in any type of omics data and were simulated by
swapping the data of two samples.

3.2.2 Duplication
Duplication error is the replication of data from one patient. This may be an electronic
duplication of the data or, more frequently, when a tissue sample is divided and
unintentionally assayed multiple times. The resulting duplicate data replaces the data for
another sample. This is often a sample associated with a different subject. To simulate a
duplicate data that accurately reflects real duplicates, actual proteomics replicates were
referred to. There are two additional actual proteomics replicates in the COAD dataset and
the replicates were found to have Pearson correlation coefficient > 0.9 with their original
counterparts. To simulate a duplicate data, the original data was added with a perturbation
equal to the standard deviation of each gene i as in Sample(i)duplicate = Sample(i) ± σ/α,
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where σ is a standard deviation of the gene i and α is a scale factor for the σ. For each gene,
the perturbation is either added to or removed from (randomly selected) the original value.
The scale factor was empirically optimized to yield correlation coefficients between
simulated duplicates similar to that observed in actual proteomics duplicates. The changes
of score difference with respect to the changes of scale factors are visualized in Figure 3.1.
Score difference is the difference of sample correlation with itself and the average of
sample correlation with others. The original data have a score difference of 0.495. A low
α increases the perturbation variance and decreases the score difference, indicating that the
duplicated data is more similar with random samples (no differences between self and other
sample), whereas a high α increases the score difference until it reaches the level of original
data (no differences with original sample). It was found that a scale factor of α = 1.0 (pivot
of the elbow line in Figure 3.1 middle) resulted in a correlation coefficient > 0.9 between
simulated RNAseq replicates and the original samples. The original data of another
randomly selected patient was discarded and displaced by the simulated data.
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Figure 3.1: Simulation of duplicated samples. (left) The actual proteomic replicates have
high sample correlation and this experimental data is used as a reference for simulation.
(middle) Simulation of the scale factor α to control sample similarity score between
RNA-seq and proteomics. Two dashed colored lines mark the sample simulation for
RNA-seq and proteomics respectively. (right) The scale factor α = 1 is chosen to simulate
RNA-seq duplicated samples which have similar sample correlation with the reference in
proteomics dataset (Figure adapted from Yoo et al., 2021).

3.2.3 Shifting
Shifting errors indicate the displacement of several samples to another sample in a
sequential manner (A to B, B to C, and C to D). Shifting errors can occur in any type of
omics data and one shifting event always involves several samples, typically ranging from
3 to 6.

3.3

Pearson Correlation Coefficient

Pearson Correlation Coefficient measures the degree of relatedness between two sets of
data. It measures the linear relationship between them and is the ratio between the
covariance of two variables and the product of their standard deviations (Equation 1 and 2).
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𝜎𝑋𝑌

𝜌𝑋, 𝑌 = 𝜎𝑋𝜎𝑌

(1)

̅)(𝑦𝑖 − 𝑦
̅)
𝜎𝑋𝑌 = ∑(𝑥𝑖 − 𝑥

(2)

Where ρX,Y = correlation of X and Y, σXY = covariance of X and Y, σX = standard
deviation of X, σY = standard deviation of Y.
When computing gene correlation across two omics data, X represents the
expression values of a specific gene in one omics data while Y represents the expression
values of a specific gene in another omics data with the same sample order as X; whereas
when computing sample correlation across two omics data, X represents the expression
values of genes of a sample in one omics data while Y represents the expression values of
the genes of a sample in another omics data with the same gene order as X.

3.4

Stable Matching Algorithm

Given a sample correlation heatmap which indicates the correlation of two samples from
two different omics data, the challenge is to find a set of matchings that each matching
pairs two samples with the highest correlation as possible. As such, we employed the GaleShapley algorithm for finding a solution to this stable matching problem (Gale & Shapley,
1962). The input of the algorithm is lists of preferential rank, one for each sample, ranking
from the highest Pearson correlation to the lowest. The preferential ranks were generated
from the sample correlation heatmap, where the ranking is done in each row for the
respective samples from omics x and in each column for the respective samples from omics
y. The output is a set of matchings, pairing two samples from different omics data.
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Below is the pseudocode of the stable matching algorithm used in this thesis:
Input: Preferential ranks for every samples
Output: A set of matchings pairing two samples, one from omics
x and one from omics y
Initialize m ∈ samples from omics x and w ∈ samples from omics
y to be unpaired
While ∃ m which is not paired with some w:
w := first sample of omics y on m's list to which m has
not yet tried to pair
if ∃ some pair (m', w) then
if w has upper rank with m to m' then
m' becomes unpaired
(m, w) become paired
end if
else
(m, w) become paired
end if
repeat

3.5

Evaluation

To evaluate the performance of the proposed approach in detecting and correcting
mislabeling, several simulation experiments were performed. In every simulation
experiment, the true datasets were used to simulate artificial datasets with mislabeling
errors as described in the previous subsection. The true individual labels of the simulated
datasets remained hidden and were used for evaluation later. The expected mislabeling rate
in real life datasets is low, ranging from 0-20%. Thus, we evaluated the proposed approach
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using F1 scores (Equation 3, 4, and 5), the harmonic mean of precision and recall. The
proposed approach should be able to detect as many mislabeled samples as possible without
overcorrecting those correctly-labeled samples.
𝐹1 =

2×𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛×𝑟𝑒𝑐𝑎𝑙𝑙
𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛+𝑟𝑒𝑐𝑎𝑙𝑙

𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =
𝑟𝑒𝑐𝑎𝑙𝑙 =

𝑇𝑃
𝑇𝑃+𝐹𝑃

𝑇𝑃
𝑇𝑃+𝐹𝑁

(3)
(4)
(5)

True positive (TP) is the number of positives correctly identified, true negative
(TN) is the number of negatives correctly identified, false positive (FP) is the number of
negatives incorrectly identified as positive, and false negative (FN) is the number of
positives incorrectly identified as negatives. Three levels of F1 scores were used in
evaluation: sample level, data level, and correction level. Each level has different criteria
to consider an instance as a true positive, with the subsequent level having stricter criterias
than the previous.
Sample level F1 score evaluates the performance of detecting samples with
mislabeled data. A positive instance is the sample with mislabeled data regardless of omics
type. If the corrected labels of any omics data do not match the original sample label, it is
considered a mislabel identification at the sample level. Data level F1 score evaluates the
performance of identifying correctly the types of mislabeled data. A true positive instance
is an instance in which all the corrected labels of omics data match the original sample
label except the mislabeled one. Correction level F1 score evaluates the performance of
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correcting the individual label. The corrected labels of all omics data should match exactly
the true labels to be considered as a true positive.
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4

MISLABELING DETECTION

This approach is based on the rationale that multiple types of omics data characterized from
the same patient have intrinsic relationship between each other and could be utilized to
extract a signal for aligning omics data. The signal should possess two characteristics: 1)
it should be general such that it could be extracted from every sample, but at the same time,
2) it should be highly specific in every individual such that every sample has a strong signal
to itself but not to other individuals.
The aim of this chapter is to investigate if such a signal could be extracted from
different omics data and how accurate the signal would be in detecting mislabeled samples.

4.1

Pairwise Alignment

4.1.1 Correlation Signal Extraction
Central Dogma of molecular biology describes the flow of genetic information from DNA
to RNA and from RNA to protein via the processes of transcription and translation. The
copy number of a gene, expression level of a gene transcript and expression level of a gene
product are correlated to some extent. The correlation between these three omics data could
be exploited to determine whether two data collections from different types of omics assays
belong to the same patient. We employ the following procedure to extract the correlation
signal that could accurately align two different omics data from the same patient.
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Figure 4.1: Imputation of sample correlation for performing pairwise alignment.

First, gene correlation between two omics data is computed and genes with high correlation
(cor > 0.5) are extracted. The expression value of these highly correlated genes are then
used to compute sample correlation between two omics data, generating a sample
correlation matrix, C with a dimension of N ✕ N.

4.1.2 Coexpression Signal Extraction for miRNA Data
It is possible to extract correlation signals between RNA-seq, proteomics and CNV
data as these omics have the same gene features. However, this is not the case for
microRNA (miRNA). MicroRNA refers to a short single-stranded RNA (~22 nt) molecule
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and mediates RNA silencing through base pair pairing. MicroRNA is not protein coding
and thus, does not have the same gene features with other omics data.
Instead of correlation signal, the coexpression signal is utilized to align miRNA
samples. Around 70% of mammalian miRNA are embedded within a host gene and these
miRNA are known as intragenic miRNA (Rodriguez et al., 2004). These miRNA were
found to share a common transcription unit with their host genes and always co-transcribe
together (Baskerville & Bartel, 2005; Ramalingam et al., 2014). The coexpression patterns
were investigated in this chapter to determine their utility in miRNA sample alignment.
To pair each miRNA with its host gene, the annotated human genome build dataset
(GRCh38.p13) was downloaded from the NCBI Ensembl7 website and the annotated
miRNA dataset (release v22) was downloaded from mirBase8. The annotated miRNA
dataset aligns to the human genome of same build GRCh38 and contains a total of 1919
unique miRNA entries. If the genomic position of a miRNA is within the genomic range
of a gene, then they are considered as a miRNA-gene pair. A total of 1647 miRNA-gene
pairs were extracted, comprising 1419 unique miRNAs and 1173 unique genes.
For every pair of miRNA and its host gene, the feature correlation was imputed
between miRNA with three other omics data (RNAseq, proteomics and CNV). Those
miRNA-gene pairs that are highly correlated were extracted. The expression value of these

7
8

http://useast.ensembl.org/index.html
http://www.mirbase.org/
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highly correlated genes were then used to compute sample correlation, generating a sample
correlation matrix, C with a dimension of N ✕ N.

4.1.3 Stable Matching for Detection
The correlation matrix C, was used as the preferential ranking for a stable matching
algorithm, with the ranking being ordered by the correlation descendingly. The stable
matching algorithm outputs N pairs of matching sample pairs with matching scores, the
sum of preferential ranks of both omics data towards each other. Ideally, omics data from
the same patient should have the top rank with each other, contributing to a matching score
of 2.
If a sample pair consists of omics data of different patients, those are considered as
mislabeled samples. The stable matching algorithm pairs exactly one-to-one omics data
thus data that are left out (due to duplication) will be paired despite having very low
correlation signals with each other. Thus, a sample pair with a matching score > N/10 were
also considered mislabeled.
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Figure 4.2: Stable Matching algorithm pairs every instance from two different omics data.

4.2

Evaluation

4.2.1 Gene Correlation Inspection
The distribution of genes Pearson Correlation between different omics was inspected. In
Figure 4.3, the gene correlations follow a normal distribution and have a mean ranging
from 0.24 to 0.53. This implies that there is a reasonable correlation between these omics
data to be used for pairwise alignments.
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Figure 4.3: Distribution of Gene Pearson Correlation between different pairs of omics
datasets: (A) Colon adenocarcinoma RNAseq and Proteomics data, (B) Clear Cell Renal
Cell Carcinoma RNAseq and Proteomics data, (C, D, E) Lung Adenocarcinoma RNAseq,
Proteomics and CNV data
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Dataset

CPTAC COAD

CPTAC
CCRCC

CPTAC LUAD

Cancer

Colon
Adenocarcinoma

Clear Cell
Renal Cell
Carcinoma

Lung Adenocarcinoma

Omics Data
(Number of
Features)

RNAseq (13172)

RNAseq
(19275)

RNAseq
(19275)

RNAseq
(19275)

Proteomics
(7556)

Omics Data
(Number of
Features)

Proteomics
(4105)

Proteomics
(10127)

Proteomics
(7556)

CNV
(19817)

CNV
(19817)

Number of
Overlapped
Features

3866

9946

7416

18707

7510

Mean of
Pearson
Correlation

0.2422

0.4099

0.5315

0.3233

0.2538

Table 4.1: Mean of gene correlation between two omics dataset

4.2.2 Simulation Experiments
To investigate if the correlation signal extracted could be a useful indicator to inform
mislabeling, the original datasets were used to simulate mislabeled datasets by the process
of bootstrapping and artificial mislabeling. In each simulation, a fixed number of omics
instances (100 in COAD; 80 in CCRCC and 80 in LUAD) were randomly selected and
mislabeling errors with an error rate of e were introduced as described in Section 3.2. The
process was repeated 10 times for each error rate, e = [0.1, 1.0].
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Figure 4.4: Simulation experiment for evaluating the performance of correlation signal in
detecting mislabeled samples. The process was repeated 10 times in each pair of omics
data for each error rate.
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The pairwise alignment algorithm was performed on each simulated dataset. Every
patient whose omics data is mislabeled, is a positive instance and only a successful
detection of the patient is treated as a true positive. The complementary principles applied
to a true negative instance. The sample level F1 score is obtained in each simulation and
shown in Figure 4.5 (A).

Figure 4.5: Sample level F1 scores of mislabeling detection between different pairs of
omics datasets: (A) across different error rates using default correlation cutoff of 0.5, (B)
across different correlation cutoff with fixed error rate of 0.2.
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Figure 4.5 (A) shows that the correlation signal could accurately align samples
across different datasets and different pairs of omics data, the average F1 score across all
the datasets is 0.99. The algorithm was shown to be robust against error rate and achieved
F1 score > 0.97 across different error rates. It is counterintuitive that the algorithm could
achieve high F1 scores when the error rate = 1.0. This is because when the error rate = 1.0,
the data do not have any useful correlation and the sample is paired randomly. Thus, all the
samples were detected as mislabeled because of random pairing that does not yield any
matching pairs. The simulation experiments were also repeated with fixed error rate, e =
0.2 but with different correlation cutoffs. This is to determine the optimum correlation
cutoff to extract gene features. Figure 4.5 (B) shows that the algorithm is robust against
different cutoffs and the F1 scores were ~0.94 across different cutoffs.

4.2.3 miRNA Coexpression Inspection
Several publications showed that miRNA always coexpress with its host genes
(Baskerville & Bartel, 2005; Ramalingam et al., 2014). The miRNA data of the lung
adenocarcinoma dataset (N = 107) was inspected and the distribution of miRNA-gene pairs
Pearson correlation was plotted (Figure 4.6). The histograms show that miRNA has
reasonable coexpression pattern to all the omics data, with the strongest correlation to
RNAseq data with a mean of 0.231 while the lowest correlation to CNV data with a mean
of 0.106.
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Figure 4.6: Distribution of Pearson correlation of miRNA-gene pairs between (A)
miRNA with RNAseq, (B) miRNA with proteomics, and (C) miRNA with CNV data of
the Lung Adenocarcinoma (LUAD) dataset.
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Alignments of omics

Number of pairs of
miRNA and host gene

Mean of Pearson
Correlation

miRNA with RNAseq

1166

0.2305

miRNA with proteomics

646

0.1331

miRNA with CNV

1182

0.1055

Table 4.2: Number of miRNA-gene pairs and the mean of Pearson correlation.

4.2.4 Simulation Experiments for miRNA Data
Simulation experiments were performed with three different pairs of omics data with
miRNA: miRNA to RNA, miRNA to Proteomics, and miRNA to CNV. The original
datasets were used to simulate mislabeled datasets (N = 100) with an error rate of 0.1. The
process was repeated 50 times and the pairwise alignment was performed on simulated
datasets iteratively using different correlation cutoffs. The performance of the pairwise
alignment algorithm in aligning miRNA data was inspected.
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Figure 4.7: Sample level F1 scores of detecting mislabeled samples in pairwise alignment
of miRNA data with three other omics data.

Figure 4.7 shows that the algorithm achieved an F1 score of 1 when aligning
miRNA with RNAseq data, whereas aligning miRNA with Proteomics data achieved the
highest F1 score of 0.68 and aligning miRNA with CNV data achieved the highest F1 score
of 0.54. The coexpression signal is proved to be useful in aligning miRNA samples with
RNA samples, but not with proteomics nor CNV data.
It is hypothesized the reason for the low F1 score in aligning miRNA to Proteomics
or CNV samples is due to low number of correlated feature pairs. To validate the
hypothesis, the simulation experiments were repeated but in each simulation, a different
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number of correlated feature pairs (corr > 0.1 or 0.2) were extracted randomly to compute
sample correlation for pairwise alignment. Figure 4.8 shows that the higher the number of
feature pairs, the higher the F1 score achieved. However, the F1 score was limited by the
number of correlated feature pairs in Proteomics and CNV data. RNAseq data has the
highest coexpression signal with miRNA data, and yet it requires at least 300 feature pairs
(corr > 0.2) to achieve an F1 score of 1. Proteomics and CNV data do not have sufficient
correlated feature pairs (corr > 0.2) to miRNA data, which normally capped at around 125
and 175 features pairs. Combined with the weaker coexpression of these datas to miRNA
data, the F1 score achieved is not sufficient for accurate label prediction. Yet, the increasing
trend of F1 score against the number of features, suggests that a higher F1 score, and thus
a useful correlation signal could be achieved if there were more feature pairs available.
One surprising finding is that the pipeline has high recall regardless of the number of
feature pairs and the low F1 score is due to low precision. This indicates that all mislabeled
samples are being identified and a matching sample can be treated as correctly labeled with
confidence.
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Figure 4.8: Sample level F1 score achieved against different number of feature pairs. The
feature pairs were selected randomly from a set of features with correlation > 0.1 (left) or
0.2 (right). Higher number of correlated feature pairs achieved a higher F1 score, but it is
limited in Proteomics and CNV data.
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4.3

Discussion

In this chapter, an algorithm was proposed to extract correlation signals between two omics
data and use the signal to perform pairwise alignments of samples. The results show that
the correlation signal is reliable and achieved a high F1 score (> 0.95) in detecting
mislabeled samples across RNAseq, Proteomics and CNV data from three cancer datasets.
The detection algorithms are robust against different error rates and achieved average F1
scores > 0.95 even in a dataset with high error rate.
The coexpression signal extracted from miRNA with RNAseq data was also shown
to be an accurate indicator to align miRNA and RNAseq samples, with an F1 score of 1.0.
However, alignment of miRNA to another two omics samples did not achieve satisfactory
F1 scores (0.68 to proteomics; 0.54 to CNV). This is due to the low number of correlated
feature pairs between these omics data. Higher number of feature pairs are required to
extract reliable coexpression signals that could accurately align proteomics and CNV
samples. It is estimated that Proteomics data requires at least 450 pairs while CNV data
requires at least 800 pairs.

44

5

MISLABELING CORRECTION IN TWO OMICS DATA

The preceding chapters show that pairwise alignment across omics data sources can
accurately detect mislabeled samples in multi omics experiments. However, alignment
alone is insufficient for correcting the identified mislabelings. To correct the label, it is
important to investigate the source of error to determine which omics data get mislabeled.
Here we propose an algorithm that utilizes the class label to determine the source of error.
The class label could be any clinical attribute collected in the dataset. In this chapter, the
aim is to investigate the accuracy obtained by using various clinical attributes as the class
label in correcting mislabeled samples.

5.1

Attribute Prediction

Other than omics data characterization, clinical attributes data of the patients are often
collected in a cohort study. Different studies collect different clinical attributes of the
patients, but sex is one of the most common attributes across all the studies. Thus, sex
phenotype and genotype was chosen to be utilized in this work for label correction.
Due to the dimensionality curse in bioinformatics data, two feature selection
methods were used. The first is the selection of sex-linked genes in sex chromosomes. The
missing values in sex-linked genes were replaced by 0 as they are assumed to be either
absent (i.e., the absence of the Y chromosome in females) or repressed (i.e., X chromosome
inactivation in females). The second method is elasticNet regularization during the model
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training. One classifier model was trained for each omics data and the model used in this
work is a regularized weighted logistic regression model. Class weighting was used to
compensate for any class imbalance issue and logistic regression (LR) model was chosen
due to its simplicity and efficiency in training.
There is an inherent circular problem in training a model to predict gender from
multi omics data from a particular study, given the possibility that sample mislabeling may
have occurred in the training data. To resolve this issue, the model is trained in two steps.
First, matched samples from the study data are used to train a model using k-fold cross
validation (CV). Next, samples for which sex genotype is mispredicted during testing folds
are identified as suspected cases of mislabeling, and are excluded from the model. Next,
the model is retrained with only high-confidence non-mislabeled samples from the study.
Finally, the re-trained model is used to predict sex genotype across all samples.
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Figure 5.1: The workflow of predicting sex label of omics data: (A) Matched samples
from the study are used in the first round of model training using k-fold cross validation
(B) Samples which sex genotype is mispredicted were identified (C) Suspected
mislabeling case is excluded from second round of model training (D) Trained model is
used to predict sex genotype across all samples.
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5.2

Individual Label Correction

With the detected mislabeled samples and predicted sex label, an automated correction
algorithm was proposed. The algorithm inspects pairwise alignment patterns along with
the predicted sex label to correct the label. There are three types of mislabeling error and
the algorithm corrects each type of error with different mechanisms.
Swapping errors are characterized by the cross alignments between two patients’
samples. To determine which omics data get swapped, the predicted sex labels of omics
data are checked against the annotated sex labels. Each checking generates an error rate,
the difference between annotated label and predicted probability. The omics data with a
higher error rate is determined to be mislabeled and the labels will be corrected.
The identification of duplication error is complicated, as the stable matching
algorithm pairs the samples in a strict one-to-one manner; a duplicated sample will not pair
with its matching sample. Hence, the identification of duplication cases relies on the
matching score. Due to the displacement of duplicated data, there is another sample with
no matching sample and will always spuriously paired with the duplicated data despite
having low correlation. Due to the low correlation, this pairing will have a high matching
score. The highest possible matching score is 2N and a threshold of 5% (2N/20) is used,
assuming that the spurious pairing will only have a 5% random chance to have a low
matching score. Thus, we used N/10 as the threshold. If a sample pair has a matching score
higher than the threshold, it is suspected to be a duplication case. To determine which omics
data get duplicated, the algorithm inspected the highest correlation each data has with the

48

other samples. The duplicated data is supposed to have high correlation with its sample,
and thus the one with the higher correlation has its label corrected.
Shifting cases always start with a duplication event. Before correcting the label, the
algorithm first identifies the shifting chain. The shifting chain starts with a duplicated
sample, which is identified as the previous paragraph. The chain is identified by iteratively
inspecting the sample pair of the last sample in the chain until the chain reaches a sample
pair with a matching score higher than the threshold N/10. After the shifting chain is
identified, the next step is to determine which omics data get shifted. The predicted sex
labels of omics data are checked against the annotated sex labels. This checking step is the
same as checking swapping errors but with several samples in the shifting chain. Each
checking generates an error rate, the difference between annotated label and predicted
probability. The omics data with a higher error rate is determined to be mislabeled and the
labels will be corrected.
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Figure 5.2: The automated correction algorithm for each type of mislabeling error.
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5.3

Simulation and Evaluation

These different algorithms (pairwise alignments, attribute prediction and label correction)
were integrated together and form an automated pipeline, known as COSMO (COrrection
of Sample by Multi Omics). To investigate the performance of COSMO in correcting
individual labels, similar simulation experiments were conducted. A dataset was simulated
with an error rate ranging from 0.05 to 0.28 and then the COSMO pipeline was used on the
dataset. The process was repeated 50 times. The performance of COSMO was evaluated
using F1 score in three levels: sample level, data level and correction level. Sample level
F1 score is the same scores obtained in Chapter 4, which evaluate performance in detecting
mislabeling of the patients’ samples. Data level F1 score evaluates how accurately the
pipeline identifies mislabeled omics type. In the data level, a mislabeled instance is treated
as a true positive if and only if COSMO detects correctly which omics data get mislabeled.
Correction level F1 score evaluates how accurate the pipeline corrects the label. In the
correction level, the corrected label has to be the same with its true label in order to be
treated as a true positive instance. Figure 5.4 represents the number of mislabeled samples
with different types of error in each simulation. The error rate ranges from 0.5 to 0.28.

51

Figure 5.3: Simulation to evaluate the correction performance of COSMO. The
simulation was repeated 50 times with various error rates.
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Figure 5.4: Number of mislabeled samples in each simulation across different datasets.
The error rate varies from 0.05 to 0.28 in every simulation.
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Figure 5.5: F1 scores of label correction across different pairs of omics data.
Sample Level
Dataset

Type of
Omics

Type of
Omics

Mean

Median

Data Level
Mean

Median

Correction
Level
Mean

Median

COAD

RNAseq

Proteomic 0.9217 0.9381 0.9123 0.9189 0.9067 0.9143

CCRCC

RNAseq

Proteomic 0.9947 1.0000 0.9906 1.0000 0.9906 1.0000

LUAD

RNAseq

Proteomic 0.9880 1.0000 0.9252 0.9393 0.9252 0.9393

LUAD

RNAseq

CNV

0.9586 0.9615 0.8700 0.8889 0.8631 0.8775

LUAD

Proteomic

CNV

0.9001 0.9091 0.7591 0.7826 0.7591 0.7826

LUAD

RNAseq

miRNA

0.9836 1.0000 0.8899 0.9062 0.8891 0.9016

Table 5.1: Mean and Median of F1 scores in sample, data and correction level
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Figure 5.5 shows that when aligning RNAseq and proteomics samples, COSMO
achieved high average F1 scores in correcting mislabeled samples: 0.91, 0.99 and 0.92 in
COAD, CCRCC and LUAD datasets in both data and correction level. When aligning
RNAseq to CNV samples, COSMO achieved an average F1 score of 0.87 in data level and
0.86 in correction level respectively. While aligning RNAseq to miRNA samples, COSMO
achieved an average F1 score of 0.89 in both levels. The results indicate that aligning
RNAseq to any other omics data is accurate, making RNAseq data the most utilisable in
detecting mislabeling. On the other hand, when aligning Proteomics to CNV data, COSMO
achieved an average F1 score of 0.76.
To determine the robustness of the pipeline in label correction, the simulation
experiments were repeated with different error rates, e = [0.1, 1.0]. The experiments are
performed using the CCRCC dataset, as it has the highest F1 scores among all datasets.
Figure 5.6 shows the F1 scores achieved against different error rates. The pipeline achieved
a mean F1 score of 1.0 when error rate = 0.1. The mean F1 score decreased with the
increasing error rate and correction level F1 score = 0.91 when error rate = 0.5. However,
the pipeline is unable to perform label correction when error rate > 0.5, due to insufficient
correctly labeled training data to train a classifier model. Without attribute prediction, the
pipeline is unable to perform label correction, albeit still able to detect mislabeled samples
(as shown in Chapter 4).
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Figure 5.6: F1 scores against different error rates.

5.4

Real Case Study - Mouse Proteogenomic Dataset

The mouse proteogenomic dataset was collected from Chick et al. (2016). This dataset was
derived from 192 mouse liver tissues and contains two types of omics data: RNAseq and
proteomics. The RNAseq data contains 21321 gene features with no missing values. The
proteomics data contains 8246 protein features: 1640 of them were removed due to missing
rate > 50%, any remaining missing values were imputed via a random-forest based
imputation, resulting in a total of 6606 protein features. The COSMO pipeline was used on
the dataset and 20 samples were found to be mislabeled.
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Among the 20 mislabeled samples, 18 were swapped (9 swapping pairs) and 2 were
duplicated. The annotated label and predicted labels of those swapped samples were shown
in Table 5.2. Four pairs were found to be proteomic swapping while the remaining five
pairs were unknown due to same-sex sample swapping.
Upon further inspection, it was observed that all 20 mislabeled samples are from
two different Tandem Mass Tag (TMT) batches, ten samples from Batch S14 and ten from
Batch S15. TMT multiplexing is a proteomic quantification technique where several
samples are tagged with unique isobaric tags, then are mixed and analyzed in a single liquid
chromatography-mass spectrometry (LC-MS) experiment. The quantification of protein
abundance and sample separation are then carried out in-silico. Every swapping case
occurred between two samples from different batches. There is reasonable evidence to
suggest that these two TMT batches got swapped, resulting in proteomic swapping in all
these 20 samples.

57

TMT
Batch

Sample

Annotated
Label

Predicted Label Predicted Label
RNAseq
Proteomic

sex

prob*

sex

prob*

sex

prob*

S14

s_130FS

F

0

F

0.0039

F

0.0811

S15

s_140FH

F

0

F

0.0147

F

0.0055

S14

s_131FS

F

0

F

0.0072

F

0.0308

S15

s_141FH

F

0

F

0.0089

F

0.0374

S14

s_132FS

F

0

F

0.0043

F

0.4644

S15

s_142FH

F

0

F

0.0129

F

0.0045

S14

s_133FH

F

0

F

0.0163

F

0.1177

S15

s_143FH

F

0

F

0.0103

F

0.0541

S14

s_135MS

M

1

M

0.8622

M

0.5750

S15

s_146FS

F

0

F

0.0112

M

0.8641

S14

s_136MS

M

1

M

0.9955

F

0.3709

S15

s_147FH

F

0

F

0.0565

M

0.9976

S14

s_137MS

M

1

M

0.9894

M

0.9999

S15

s_148MH

M

1

M

0.9948

M

0.9992

S14

s_138MH

M

1

M

0.9779

F

0.0754

S15

s_149FH

F

0

F

0.0108

M

0.9844

S14

s_139MS

M

1

M

0.9944

F

0.2745

S15

s_150FH

F

0

F

0.0167

M

0.9995

Type of
Swapped
data
Unable to
infer
Unable to
infer
Unable to
infer
Unable to
infer
Proteomic

Proteomic

Unable to
infer
Proteomic

Proteomic

Table 5.2: The annotated and predicted labels of 18 swapped samples. Every two
consecutive samples, indicated by different colored cells, are swapped with each other.
The prediction probability is the probability of being a male sample. The table is adapted
from Yoo et al. (2021).
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Figure 5.7: Four pairs of swapping were determined to be proteomics swapping. Though
it is impossible to determine the source of error for another 5 pairs of swapping, the
observation that every swapping occurred between samples from two different TMT
batches suggests the Proteomics data get swapped during TMT multiplexing process.

The mislabeling rate in this dataset is 10.4% (20/192). To determine the impact of
mislabeling in the analysis, the protein Quantitative Trait Loci (pQTL) analysis was rerun
on the corrected data. In the published data, the most significant association is the OMA1
protein expression of OMA1 to a genetic marker in Chromosome 4 with a log odd ratio of
24. After correcting the data, the log odd ratio increased to 31, an increment by 1.3 fold
(Figure 5.8).
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Figure 5.8: LOD score of OMA1 protein expression with a genetic marker in
Chromosome 4 increased from 24 to 31 upon rerun the pQTL analysis on corrected data
The figure was adapted from Yoo et al. (2021).

5.5

Discussion

The COSMO pipeline is useful in detecting the mislabeled samples and determining the
source of error before correcting the labels. It was shown to have achieved high F1 scores
in both data level and correction level, on three simulated cancer datasets. Mislabeling
correction has the highest F1 score when comparing RNAseq data to Proteomics data, with
an average score > 0.9 (both data and correction level) in all three datasets. It was observed
that COSMO achieved the highest average F1 score of 0.99 in Kidney Cancer Dataset
(CCRCC). This could be due to the higher number of protein features (CCRCC has 10127
protein features while COAD has 4105 and LUAD has 7556) which helps in extracting
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more reliable correlation signals. Mislabeling correction in RNAseq to CNV or to miRNA
data also has a high average F1 score (> 0.86 in both data and correction level). This shows
that RNAseq is the most utilisable omics data in detecting and correcting mislabeled
samples. On the other hand, mislabeling corrections in Proteomics to CNV data achieved
an average F1 score of 0.76. There is still room for improvements. Fortunately, this does
not diminish the impact of COSMO as it still has a high detection capability (as shown in
Chapter 4). Besides, RNAseq data is the most common omics data to be characterized in
the research settings and most of the studies have RNAseq data which could be utilized in
correcting Proteomics and CNV data.
To showcase the impact of COSMO, the pipeline was carried out on a real
proteogenomic dataset to perform a quality check. It was found that 10.4% (20/192) of
proteomics data get mislabeled. The pQTL analysis was rerun on corrected proteomics data
and the most significant association (OMA1 protein expression with a genetic variant in
Chromosome 4) has increased LOD score from 24 to 31, showing that a small mislabeling
rate of 10.4% can have an impact of reducing the significance by 23% (7 / 31) on the LOD
score.
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6

MISLABELING CORRECTION IN MULTI OMICS DATA

COSMO has achieved good performance in detecting and correcting mislabeling, but its
application is limited to datasets with exactly two omics data. Theoretically, a study with
more than two omics data could perform the same pipeline iteratively for different pairs of
omics data, but each application only utilizes information from the two omics data being
inspected and do not approach the task in a holistic manner. The advantage of having more
types of omics data is not fully exploitable since more dimensions of omics data is
hypothesized to have more information in mislabeling handling. Besides, each application
performs predictions for two omics data and it is redundant in consecutive applications
where the same omics data were corrected. The redundancy decreases the efficiency of the
quality control check and the reduction is even higher if a dataset has more types of omics
data. In Chapter 6, an algorithm was proposed to integrate all omics data to detect and
correct individual mislabeling in a dataset. The performance of the proposed algorithm was
investigated, along with its application in real life datasets.

6.1

Network Topology Realignment

Considering a patient’s tissue sample was used to characterize three types of omics data
(RNAseq, proteomics and CNV), these three different data instances should have the
highest correlation signal with each other. In other words, three pairwise alignments will
be performed: RNAseq to proteomics, RNAseq to CNV, and proteomics to CNV. In each
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alignment, the data instances from the same patient should have the highest correlation
signal and are paired with each other.
Thus, the mislabeling detection and correction tasks could be approached as a
network topology realignment task. An algorithm was proposed to integrate all pairwise
alignments to perform the realignment. In the network, the set of vertices consists of all
data instances of every omics data and the edge represents the matching pairs in each
pairwise alignments. Data instances from the same patient should have the highest
correlation signal with each other, and thus they should be connected with only each other,
forming a tightly connected cluster on the network. These data instances are considered as
correctly labeled whereas those that do not pair with itself are considered mislabeled. Then,
those considered mislabeled will have their correlation to other omics inspected to perform
label correction.
During label correction, the priority of the mislabeled instances were determined.
Priority indicates the number of mismatches in each pairwise alignment. The instance with
the highest priority will have its label get corrected first. To determine the correct label of
the instance, its correlation to other instances from different omics was inspected for every
patient and the one with the highest correlation will be the corrected label. As the instance
gets corrected, it forms a new connected cluster. All the instances within the cluster will
have their priority updated. The label correction process repeats until all the instances have
their label corrected or their priority becomes zero.
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Figure 6.1: Network Topology Realignment for correcting the labels for datasets with
more than two types of omics data. Mismatched instances will get their labels corrected.
The correction process keeps iterating until all mismatched instances get corrected or
become zero priority.
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6.2

Simulation and Evaluation

A mislabeled dataset was simulated from LUAD dataset with four omics data: RNAseq,
proteomics, CNV and miRNA data. A total of 100 patients were randomly selected and
mislabeling errors were artificially introduced to the dataset. Pairwise alignments were
performed on the simulated dataset and the alignments output were used to handle
mislabeling via network topology realignment. The performance was evaluated using F1
scores in three levels: sample level (if a sample has mislabeled data), data level (if a data
instance is mislabeled), and correction level (if a mislabeled instance is corrected to its true
label). The process was repeated 10 times for each error rate where error rate = [0.1, 1.0].

Figure 6.2: F1 scores of network topology realignment in multi omics data across
different error rates.
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Error Rate

Sample Level

Data Level

Correction Level

Mean

Median

Mean

Median

Mean

Median

0.1

0.9846

1.0000

0.9458

0.9706

0.9458

0.9706

0.2

0.9937

1.0000

0.9709

0.9697

0.9603

0.9687

0.3

0.9921

1.0000

0.9554

0.9583

0.9421

0.9545

0.4

0.9986

1.0000

0.9669

0.9677

0.9605

0.9677

0.5

0.9938

1.0000

0.9656

0.9740

0.9522

0.9538

0.6

0.9916

0.9899

0.9658

0.9684

0.9488

0.9519

0.7

0.9953

1.0000

0.9515

0.9557

0.9369

0.9423

0.8

0.9937

0.9963

0.9545

0.9593

0.9388

0.9447

0.9

0.9959

0.9966

0.9578

0.9603

0.9364

0.9382

1.0

0.9969

0.9971

0.9638

0.9697

0.9443

0.9425

Table 6.1: Mean and Median F1 scores of label correction across different error rates.

Figure 6.2 shows that the network realignment algorithm achieved high F1 scores
(> 0.99 in patient level, > 0.95 in data level and > 0.94 in correction level) across different
error rates. The algorithm is robust against error rates even at the correction level. This
emphasizes the advantage of having more than two omics data, the misalignment of one
data could be corrected by other pairwise alignments. It should be noted that the error rate
indicates the proportion of samples with mislabeled data. In other words, a dataset with an
error rate of 1.0 indicates that every sample has one mislabeled data. The label correction
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is still feasible in such high error rate as the mislabeled data could be realign to other
correctly labeled omics data.

6.3

Real Case Study

6.3.1

TCGA Breast Cancer Dataset (BRCA)

TCGA is the largest public multi omics repository to date. Breast Invasive Carcinoma
dataset is the largest cancer dataset to date. It consists of data of 521 patients with all three
types of omics data collected: RNAseq, microarray and CNV. The omics quantification
pipelines were described in detail on the website 9. The omics data contains 20501, 17274,
and 25187 gene features respectively with no missing values. Three pairwise alignments
were performed and network realignment identified 16 mislabeled samples. These 16
samples were swapped in microarray data and the samples were listed in Table 6.2.
Breast cancer dataset is highly gender imbalanced in that most of the samples
belong to female patients. Only 0.1% (6 / 521) of the samples belong to male patients.
Table 6.2 shows that one mislabeled sample belongs to male patient. To investigate the
impact of the mislabeling, the differential expressed gene (DEG) analysis was run between
male and female patients. T-test was performed on each gene feature between two groups
and the significance of the gene was adjusted by Benjamini-Hochberg procedure. The
analysis was run twice, first on the mislabeled data and then corrected data. The number of

9

https://docs.gdc.cancer.gov/Data/Introduction/
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DEGs are shown in Figure 6.3. In the first run, 16 genes were found to be differentially
expressed while in the second run, the number of DEG increased to 59, an increment of 3.7
fold. Among these two sets of DEGs, 13 of them overlapped which means the mislabeling
prevented the discovery of 46 true DEGs. Three genes, previously thought to be significant,
are in fact not significant (Figure 6.4).

First sample in a pair

Second sample in a pair

Label

Sex

Label

Sex

TCGA.BH.A0BA

Female

TCGA.BH.A0DS

Female

TCGA.BH.A18K

Female

TCGA.BH.A18T

Female

TCGA.BH.A0BS

Female

TCGA.BH.A0BT

Female

TCGA.AR.A1AW

Female

TCGA.AR.A1AV

Male

TCGA.BH.A0H3

Female

TCGA.BH.A0HA

Female

TCGA.E2.A1B5

Female

TCGA.E2.A1B6

Female

TCGA.AR.A1AN

Female

TCGA.AR.A1AL

Female

TCGA.BH.A0EI

Female

TCGA.A1.A0SD

Female

Table 6.2: Eight swapping pairs of 16 mislabeled microarray data. Each row represents
each swapping pair.

68

Figure 6.3: Number of DEGs before and after correction across different thresholds.

Figure 6.4: Change of false discovery rate of genes before and after the correction.
Horizontal and vertical grey lines indicate the FDR cutoff of 0.05.
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6.3.2 Lymphoblastoid cell lines (LCLs) dataset
Battle et al. (2015) conducted a study to determine the association of genetic markers with
expression quantitative trait loci (eQTLs), ribosome occupancy (rQTLs), or protein
abundance (pQTLs). Three types of omics data were generated from Epstein-Barr virus
(EBV)-transformed lymphoblastoid cell lines (LCLs) derived from 60 human individuals.
RNAseq and Riboseq were quantified based on Fragments Per Kilobase of transcript per
Million mapped reads (FPKM) as described in the study. Protein abundance was measured
using a SILAC internal standard sample (Ong et al., 2002) and quantitative protein mass
spectrometry. RNAseq data contains 16614 gene features while the riboseq data contains
15059 genes with no missing values. The proteomics data contains 4381 proteins and the
missing values were imputed by random forest based imputation.
Battle et al. (2015) observed that many QTLs exhibit shared effects across mRNA,
ribosome occupancy (riboseq) and protein, indicating that riboseq has reasonable
correlation to RNAseq and proteomics data. Three pairwise alignments were performed
and the distribution of gene correlation across different pairs of omics data were inspected.
Figure 6.5 shows that the Pearson Correlation follows normal distribution in every pair of
omics data. Riboseq is a high throughput method based on deep sequencing of ribosomeprotected mRNA fragments, providing an estimate of protein translation efficiency. Thus,
riboseq has a higher mean correlation to RNAseq and to Proteomics, compared to the mean
correlation of RNAseq to proteomics data.
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Figure 6.5: Distribution of gene-wise Pearson Correlation across different pairs of omics
data.

The alignment outputs were feedforward to the network realignment algorithm.
Three samples were found mislabeled. Two RNAseq data were found to be swapped, while
one proteomics data was found to be duplicated. The mislabeling rate of the dataset is 5%
(3 / 60).

Figure 6.6: Three Mislabeled samples found in LCLs dataset.
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6.3.3 Tuberculosis Patients Blood Gene Expression
Cliff et al. (2013) conducted a study on 27 tuberculosis patients with the aim to differentiate
blood gene expression with respect to the treatment response. The patients were given
conventional therapy (2HRZE/4HR) for 6 months: isoniazid, rifampin, pyrazinamide and
ethambutol for 2 months (2HRZE) followed by isoniazid plus rifampin for 4 months
(4HR). During the treatment duration, blood samples were collected in five different
timepoints: prior to starting standard therapy and after 1, 2, 4, and 26 weeks of successful
treatment. In total, 135 blood samples were collected (27 patients ✕ 5 timepoints). The
gene expression of blood samples was characterized using the microarray platform AAFFY-44 - Affymetrix GeneChip Human Genome U133 Plus 2.0, measuring expression
of 21319 genes in every sample.
There is only one type of omics data in this dataset (transcriptomics) but the patients
have their blood samples collected five times in five different timepoints. Ten pairwise
alignments were performed across all different pairs of timepoints and the alignment
outputs were used for network realignment. A total of 25 samples from 17 patients were
found to be mislabeled, as shown in Figure 6.7. No sample was mislabeled at the time of
diagnosis and one week after treatment. In the second week, 10 samples were mislabeled
in two shifting events (each shifting involved 5 samples). In the fourth week, 5 samples
were mislabeled: two of them swapped while three got shifted. At the last timepoint 26th
week, 10 samples got shifted in one shifting event.
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Figure 6.7: Mislabeling of 25 samples from 17 patients. Patients whose samples are not
shown here are correctly labeled. There is no mismatched sample in Week 0 and Week 1.
In week 2, there are two shifting events, indicated by different colors of edges. In week 4,
the shifting events are indicated by blue-colored edges. Only mismatched edges are
shown here.

The paired t-test was conducted between Week 4 and Week 26 after label
correction. The number of genes found to be differentially expressed is 3844 before
correction and 4019 after label correction. Among these two sets of DEGs, 3709 genes
overlapped. In other words, the mislabeling prevented the discovery of 310 genes, 7.71%
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(310 / 4019) of the total number of genes. There are 135 previously identified DEGs that
are in fact not significant (Figure 6.9).

Figure 6.8: Number of differentially expressed probes (left) and genes (right) between
Week 4 and Week 26 before and after the label correction.
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Figure 6.9: Change of false discovery rate of probes before and after the correction.
Horizontal and vertical grey lines indicate the FDR cutoff of 0.05.

6.4

Prevalence

The mislabeling pipeline was applied on other public datasets to detect any mislabeling
and determine the mislabeling rate overall. Cancer Cell Line Encyclopedia (CCLE) is a
multi omics repository of several human cancer cell lines (Ghandi et al., 2019). To date,
the repository contains data of 1457 cell lines. Three types of omics data were collected
from the website10: RNAseq, proteomics and CNV. Cell lines that do not have all three
omics data were filtered, leaving 371 cell lines at the end. Three pairwise alignments were

10

https://portals.broadinstitute.org/ccle
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performed on the dataset followed by network realignment. All cell lines aligned perfectly
with each other and no mislabeling was found.
TCGA is the largest public multi omics repository to date, consisting of 38 different
cancers. Nine cancer datasets having all four types of omics data were collected (RNAseq,
microarray, CNV and miRNA) and the mislabeling detection algorithm was applied on
these datasets. Table 6.3 shows the summary statistics of mislabeled samples.

The

mislabeled samples were found in 5 (55.55%) out of 9 cancer datasets. In total, there are a
total of 1259 subjects and 44 (3.49%) of them whose data has been mislabeled. The
mislabeling rates vary across datasets, ranging from 0% to 28.13%.
Cancer
Dataset

Number of Subjects with
Subjects mislabeled data

Omics
Assay

Sample
Size

Mislabeled
Assay

Rate
(%)

BRCA

521

18 (3.45%)

RNAseq
Microarray
CNV
miRNA
Total

521
521
521
312
1875

0
16
0
2
18

0
3.07
0
0.64
0.96

COAD

135

8 (5.93%)

RNAseq
Microarray
CNV
miRNA
Total

135
135
135
121
526

0
5
0
3
8

0
3.70
0
2.48
1.52

GBM

19

0 (0%)

RNAseq
Microarray
CNV
Total

19
19
18
56

0
0
0
0

0
0
0
0

KIRC

71

4 (5.63%)

RNAseq
Microarray
CNV

71
71
69

0
3
0

0
4.23
0
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miRNA
Total

62
273

1
4

1.61
1.47

KIRP

16

0 (0%)

RNAseq
Microarray
CNV
miRNA
Total

16
16
16
16
64

0
0
0
0
0

0
0
0
0
0

LGG

27

0 (0%)

RNAseq
Microarray
CNV
miRNA
Total

27
27
27
27
108

0
0
0
0
0

0
0
0
0
0

LUAD

32

9 (28.13%)

RNAseq
Microarray
CNV
miRNA
Total

32
32
32
32
128

0
0
9 28.13
0
0
0
0
9 7.03

LUSC

151

0 (0%)

RNAseq
Microarray
CNV
miRNA
Total

151
151
151
127
580

0
0
0
0
0

0
0
0
0
0

OV

287

5 (1.74%)

RNAseq
Microarray
CNV
miRNA
Total

287
287
284
280
1138

0
0
0
5
5

0
0
0
1.79
0.44

Total

1259

44 (3.49%)

4748

44

0.93

Table 6.3: Summary of mislabeled samples found in TCGA datasets.

Expression Atlas is an archive storing gene expression data from high-throughput
experiments housed by EBI (European Bioinformatics Institute). Expression Atlas stores
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and displays gene expression data across species and biological conditions, which enables
the user to retrieve desirable datasets. The mislabeling detection algorithm is applicable to
datasets in which every subject contributes at least 2 samples. The datasets of homo sapiens
from differential experiments were collected where the experimental factor is time or
treatment. Datasets were filtered based on these criterias: 1) contributed by too few subjects
(< 8 subjects and < 16 assays), 2) the assays are generated by the same cell line and no
heterogeneity in different samples. A total of 48 datasets were collected, consisting of 6900
assays contributed by 1993 subjects. The application of the proposed approach revealed
eight datasets (16.67%) to have mislabeled data (as listed in Table 6.4 and appendix A). In
overall, 36 (1.81%) subjects have their data mislabeled, affecting a total of 44 (0.64%)
assays.
Number of
Subjects

Subjects with
Mislabeled Data

Number of
Assays

Mislabeled
Assays

E-MTAB-6558

107

3 (2.80%)

288

3 (1.04%)

E-GEOD-19519

112

1 (0.89%)

224

1 (0.45%)

E-MTAB-7032

61

3 (4.92%)

158

3 (1.90%)

E-GEOD-41168

42

3 (7.14%)

140

3 (2.14%)

E-GEOD-31348

27

17 (62.96%)

135

25 (18.52%)

E-GEOD-58558

19

2 (10.53%)

109

2 (1.83%)

E-GEOD-23597

42

1 (2.38%)

107

1 (0.93%)

E-TABM-1138

142

6 (4.23%)

284

6 (2.11%)

Table 6.4: Datasets collected from Expression Atlas which contain mislabeled data.
Details of other datasets could be found in Appendix A.
78

To determine the overall prevalence of mislabeling in public omics datasets, the
summary of the mislabeled samples was compiled and inspected in respect to studies,
subjects and assays. The study refers to a project or an experiment which generates the
dataset. The subject refers to the organism where the biological sample is collected from.
In a multi-omic study, one subject contributes one biological sample; but in a multitimepoint study, one subject could contribute multiple biological samples. Hence, the
number of subjects instead of samples is compiled in this table. The assay refers to any
omics data generated in the study. In a multi-omic study, one sample is sequenced for
several omics types but in a multi-timepoint study, one sample is only assayed for one
omics data. The number of assay is the number of data generated regardless of the types of
omics.
Table 6.5 shows that 25% of datasets contain mislabeled data. These datasets
consist of omics data from 3875 subjects and 105 (2.71%) subjects’ data have been
mislabeled. Looking further into the performed assays, 113 (0.85%) out of 13325 assays
were mislabeled. Given that most of the multi-omic studies combine omics data to perform
integrative analysis, it is more practical to look into the mislabeling rate in subject level
than assay level. Although there is only less than 1% of mislabeled assays, it results in a
much higher mislabeling rate in subject level, highlighting again the importance of
performing quality check before data analysis.
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Number
Studies
Number
Number of
of
Containing
of
Subjects with
Datasets/ Mislabeled Subjects
mislabeled
Studies
Samples
data

Number
of
Assays

Number of
Mislabeled
Assay

Chick et al.
(2016)

1

1

192

20

384

20

TCGA

9

5

1259

44

4748

44

Battle et al.
(2016)

1

1

60

5

180

5

CCLE

1

0

371

0

1113

0

Expression
Atlas

48

8

1993

36

6900

44

Total

60

15 (25%)

3875

105 (2.71%)

13325

113
(0.85%)

Table 6.5: Overall mislabeling rate compiled from various sources of datasets.
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7

CONCLUSION AND FUTURE WORK

Multi omics study is getting more common in recent years. It characterizes several types
of omics data and takes a system biology approach to gain insight in understanding
biological processes. The scale of the study is getting larger and more omics data are
generated, contributed by the collaborative efforts of researchers. The large scale of the
study does not come by without any consequences. Sample mislabeling is a prevalent
problem in multi omics studies and has led to unwanted consequences: irreproducibility of
the result, unnecessary research effort and cost, and the discovery of false claims.
While the large scale of the multi omics study poses a risk of sample mislabeling,
the multi dimension of omics data generated in the study presents an opportunity to perform
quality check, making sure the data is attributed to the correct label before doing any data
analysis. In this thesis, the quality check is approached as alignment tasks. The omics data
from the same patient that are aligned together are considered correctly labeled and vice
versa. Chapter 4 shows that every individual contains a unique signal in the omics data that
is useful in the sample alignment. A method was proposed to extract correlation /
coexpression signals and the signals are shown to be reliable in performing sample
alignment. The method was able to achieve F1 scores of at least 0.95 in detecting
mislabeling and is robust against error rate.
The pairwise alignments outputs were further inspected to correct the individual
labels of the samples in a study where only two types of omics data are available. A pipeline
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was proposed to integrate predicted sex genotype in the label correction task. Chapter 5
shows that the pipeline was able to achieve F1 scores of at least 0.88 in correcting the labels
when comparing RNAseq data to any other types of omics data. The utilization of predicted
genotype enables the label correction task and the limitation lies in this component as well.
To accurately correct the label, the prediction has to be accurate and to be able to correct
the label, the mislabeled samples should have the opposite class label in the first place to
begin with. The pipeline was applied on a real dataset (Battle et al., 2015). Nine pairs of
samples were found to be swapped, however, the algorithm was unable to determine the
source of error for 5 pairs as the swapping occurred between same sex sample. Fortunately,
manual inspection revealed the swapping occurred between two TMT batches during
proteomic multiplexing measurements, suggesting the source of error is on proteomics
data. Though only sex attribute was utilized in the work here, theoretically, any other
attribute that could be accurately predicted from omics data should enable the label
correction task as well.
For datasets with more than 2 types of omics data, an algorithm was proposed to
realign the data. The algorithm was able to achieve F1 scores of at least 0.94 in correcting
individual labels. Due to the presence of at least 3 types of omics data, more pairwise
alignments are performed and one mislabeled data could be realigned with another omics
data without the attribute prediction. This mitigates the limitation of the previous pipeline
and showcases the advantage of having more dimensions of omics data. Besides, more
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dimensions of omics data enable the network realignment algorithm to be robust against
error rate.
Several datasets were collected from public repositories and the correction
pipelines were performed to detect the mislabeled samples. Overall, 2.71% (105 / 3875) of
the subjects are found to have mislabeled data. Though most of the datasets were free of
any mislabeling, one dataset was observed to have a mislabeling rate as high as 28.13%.
This showed the significance of performing quality checks in multi omics studies. An
automated correction algorithm was developed to detect and correct the mislabeled samples
to the individual level. The omics data inspected in this work are transcriptomics,
proteomics, CNV and miRNA. One of the future directions includes investigating the
quality check pipeline for other omics data such as genomic, epigenomic, metabolomic,
phosphoproteomic and others.
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APPENDIX A
Table A: All 48 datasets collected from Expression Atlas, along with the number of
mislabeled data and mislabeled assay in each dataset. A subset of the table is used to create
Table 6.4, which contains only datasets with mislabeled data.
Number of
Subjects

Subjects with
mislabeled data

Number of
Assay

Mislabeled
Assay

E-GEOD-100833

289

0

1653

0

E-MTAB-2232

377

0

1399

0

E-MTAB-6559

125

0

369

0

E-MTAB-6558

107

3

288

3

E-GEOD-19519

112

1

224

1

E-GEOD-20181

57

0

171

0

E-MTAB-7032

61

3

158

3

E-GEOD-41168

42

3

140

3

E-GEOD-31348

27

17

135

25

E-GEOD-58558

19

2

109

2

E-GEOD-63085

29

0

84

0

E-GEOD-11348

31

0

93

0

E-GEOD-53552

25

0

96

0

E-GEOD-11903

15

0

85

0

E-GEOD-41663

15

0

81

0

E-GEOD-23597

42

1

107

1

E-TABM-1138

142

6

284

6

Dataset ID

93

E-MEXP-3756

20

0

40

0

E-MEXP-2069

20

0

60

0

E-GEOD-20489

11

0

54

0

E-MTAB-8549

27

0

54

0

E-MTAB-6212

15

0

45

0

E-TABM-740

18

0

36

0

E-MTAB-5262

10

0

35

0

E-GEOD-18995

16

0

32

0

E-GEOD-48445

15

0

30

0

E-GEOD-31652

13

0

26

0

E-MTAB-7456

15

0

30

0

E-MTAB-6555

10

0

30

0

E-MTAB-7087

8

0

23

0

E-GEOD-29908

9

0

18

0

E-GEOD-11227

8

0

16

0

E-MTAB-6556

10

0

180

0

E-TABM-271

8

0

32

0

E-MTAB-6473

8

0

32

0

E-MEXP-941

8

0

32

0

E-GEOD-26104

8

0

32

0

E-GEOD-80060

74

0

148

0

E-GEOD-60424

20

0

134

0

E-GEOD-21610

30

0

60

0

94

E-GEOD-32407

10

0

60

0

E-GEOD-60590

14

0

32

0

E-GEOD-22278

16

0

32

0

E-GEOD-16797

17

0

34

0

E-GEOD-46665

9

0

25

0

E-GEOD-11199

12

0

24

0

E-MEXP-1901

8

0

16

0

E-GEOD-11100

11

0

22

0

1993

36 (1.81%)

6900

44 (0.64%)

Total

95

